Skip to main content

Table 2 Comparative analysis of patients with normal and prolonged QTc interval

From: Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study

VariablesQTc intervalp-value
Normal (N = 382) a
n (%)
Prolonged (N = 23) b
n (%)
Gender
 Male229 (92.3)19 (7.7)0.03
 Female153 (97.5)4 (2.5)
Age (years)
  ≤ 2075 (19.6)6 (26.1)0.45
 21–30105 (27.5)4 (17.4)
 31–4094 (24.6)4 (17.4)
  > 40108 (28.3)9 (39.1)
All prescribed drugs
 147 (12.3)1 (4.3)0.48
 2–3240 (62.8)15 (65.2)
  > 395 (24.9)7 (30.4)
QT prolonging drugs
 1216 (56.5)10 (43.5)0.22
  ≥ 2166 (43.5)13 (56.5)
QT drug-drug interactions109 (28.5)9 (39.9)0.27
Diagnosis
 Psychosis29 (7.6)2 (8.7)0.84
 Manic depressive psychosis33 (8.6)10 (13)0.47
 Obsessive compulsive disorder16 (4.2)2 (8.7)0.30
 Schizophrenia16 (4.2)1 (4.3)0.97
 Major depression200 (52.4)11 (47.8)0.67
 Hypomania13 (3.4)0 (0)0.36
 Panic disorder34 (8.9)0 (0)0.13
 Bipolar affective disorder11 (2.9)0 (0)0.40
 Substance abuse17 (4.9)0 (0)0.30
Co-morbid illnesses
 Hypertension40 (10.5)3 (13)0.67
 Diabetes mellitus17 (4.5)0 (0)0.80
 Epilepsy13 (3.4)0 (0)0.27
QT prolonging drug classes (ATC Code)
 Antipsychotic (N05A)140 (36.6)11 (47.8)0.28
 Proton pump inhibitors (A02BC)48 (12.6)1 (4.3)0.24
 Antidepressant (N06A)253 (66.2)14 (60.9)0.59
 Other drugs19 (5)2 (8.7)0.43
  1. a Percentage calculated in total of 382 patients with normal QTc interval except gender; b Percentage calculated in total of 23 patients with prolonged QTc interval except gender